Several new treatments are transforming diabetes care, with Retatrutide, Cagrillintide, Tirzepatide, and Semaglutide standing out leading candidates. Retatrutide, a twin GIP and GLP-1 receptor agonist, exhibits significant weight loss coupled with better glycemic regulation. Cagrillintide, a GLP-